Login / Signup

Hepatitis C virus RNA is 5'-capped with flavin adenine dinucleotide.

Anna V SherwoodLizandro R Rivera-RangelLine A RybergHelena S LarsenKlara M AnkerRui CostaCathrine B VågbøEva JakljevičLong V PhamCarlota Fernandez-AntunezGabriele IndrisiunaiteAgnieszka Podolska-CharleryJulius E R GrothenNicklas W LangvadNicolas FossatAnna OffersgaardAmal Al-ChaerLouise NielsenAnna KuśnierczykChristina SølundNina WeisJudith Margarete GottweinKenn HolmbeckSandro BottaroSantseharay RamirezJens BukhTroels Kasper Høyer ScheelJeppe Vinther
Published in: Nature (2023)
RNA viruses have evolved elaborate strategies to protect their genomes, including 5' capping. However, until now no RNA 5' cap has been identified for hepatitis C virus 1,2 (HCV), which causes chronic infection, liver cirrhosis and cancer 3 . Here we demonstrate that the cellular metabolite flavin adenine dinucleotide (FAD) is used as a non-canonical initiating nucleotide by the viral RNA-dependent RNA polymerase, resulting in a 5'-FAD cap on the HCV RNA. The HCV FAD-capping frequency is around 75%, which is the highest observed for any RNA metabolite cap across all kingdoms of life 4-8 . FAD capping is conserved among HCV isolates for the replication-intermediate negative strand and partially for the positive strand. It is also observed in vivo on HCV RNA isolated from patient samples and from the liver and serum of a human liver chimeric mouse model. Furthermore, we show that 5'-FAD capping protects RNA from RIG-I mediated innate immune recognition but does not stabilize the HCV RNA. These results establish capping with cellular metabolites as a novel viral RNA-capping strategy, which could be used by other viruses and affect anti-viral treatment outcomes and persistence of infection.
Keyphrases
  • hepatitis c virus
  • human immunodeficiency virus
  • nucleic acid
  • mouse model
  • sars cov
  • squamous cell carcinoma
  • innate immune
  • ms ms
  • genetic diversity
  • antiretroviral therapy